<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062175</url>
  </required_header>
  <id_info>
    <org_study_id>55</org_study_id>
    <nct_id>NCT04062175</nct_id>
  </id_info>
  <brief_title>Efficacy of Adding Azithromycin to Cephalosporin Before Cesarean Delivery</brief_title>
  <official_title>Efficacy of Adding Azithromycin to Cephalosporin for the Prophylaxis Against Infectious Morbidity Following Cesarean Delivery in High Risk Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      efficacy of adding azithromycin to cephalosporin before cesarean delivery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      efficacy of adding azithromycin to cephalosporin for the prophylaxis against infectious
      morbidity following cesarean delivery in high risk women
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Actual">July 18, 2019</completion_date>
  <primary_completion_date type="Actual">June 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of women with wound infection</measure>
    <time_frame>after 14 days post cesarean delivery</time_frame>
    <description>superficial and deep surgical site wound infection will be looked for by laboratory confirmation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>% of women with postpartum endometritis</measure>
    <time_frame>after 14 days post cesarean delivery</time_frame>
    <description>fever, abdominal pain , uterine tenderness will be looked for</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>Wound Sepsis</condition>
  <arm_group>
    <arm_group_label>cephalosporin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>72 women will receive single antibiotic chemotheraby first generation cephalosporin (cefazolin) 2 gm iv within 30 minutes before skin incision</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cephalosporin +azithromycin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>72 women will receive combined antibiotic chemotherapy azithromycin (Azrolid) 1 gm single oral dose 2 hours before cesarean delivery + cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cephalosporin</intervention_name>
    <description>72 women will receive single antibiotic chemotherapy(Cefazolin) 2 gm iv within 30 minutes before skin incision</description>
    <arm_group_label>cephalosporin +azithromycin arm</arm_group_label>
    <arm_group_label>cephalosporin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin Tablets</intervention_name>
    <description>72 women will receive combined antibiotic chemotherapy azithromycin(Azrolid) 1 gm single oral dose 2 hours before cesarean delivery +cephalosporin(Cefazolin) 2 gm iv within 30 minutes before skin incision</description>
    <arm_group_label>cephalosporin +azithromycin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age between 17 and 39 years

          -  gestaional age between 37 to 42 weeks

          -  elective cesarean delivery

          -  obese women

        Exclusion Criteria:

          -  diabetic women on corticosteroids

          -  intraopertaive complication in previous section

          -  history of septic woun

          -  prelabour rupture of membrane &gt;12 hours
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reda Mokhtar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams university ,egypt el abbasia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams maternity hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>August 18, 2019</last_update_submitted>
  <last_update_submitted_qc>August 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Ghada fayed hashem el sharkawy</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

